Syndax Pharmaceuticals reported strong Q2 2026 results with total revenue of $73 million, up 92% year-over-year, driven by Revuforj net revenue of $54.7 million and Niktimvo net revenue of $60.3 million. The company highlighted ongoing clinical trials and pipeline expansion, including new drug candidates for lung cancer and myelofibrosis. Upcoming data releases from Phase 2 trials of axatilimab in IPF and frontline cGVHD are expected in Q4 2026, supporting future growth prospects. Syndax also expects to reach profitability with its current cash and revenue streams.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
Arm's stock fluctuated significantly in 2026 due to shifts in customer demand and supply confidence for its silicon manufacturing. Despite steady demand figures, the stock fell earlier in the year due to supply concerns but rallied strongly in Septem...
Bob's Discount Furniture is showing robust growth despite tough market conditions, with a market cap of $2.07 billion. Management aims to expand to 500 showrooms by 2035, achieve 9% annual revenue growth, and reach EBITDA of $683.7 million through di...
Bitcoin surged past $86,000, gaining 6% in a day and pushing its market cap to $1.72 trillion, close to its 2026 opening price of $87,575. The rally was driven by a massive short squeeze liquidating over $454 million in short positions within 24 hour...
